Ataxia Clinical Training

Ataxia Clinical Training (ACT)

Two-day program to acquire practical knowledge about the diagnostic investigation and treatment of the Ataxias.

ACT II | MARCH 30 - APRIL 1, 2023

NAF’s Ataxia Clinical Training (ACT) program debuted in March 2022. The primary objective of this training session was to acquire practical knowledge about the diagnostic investigation and treatment of the Ataxias through a series of didactic talks by clinicians who have significant experience in this area. The attendees were also introduced to ongoing research in the field of Ataxia and had the ability to personally interact with patients and families affected by a wide-spectrum of Ataxic disorders. The ACT included topics on diagnostic approach to Ataxias, heredodegenerative and Acquired Ataxias, neurogenetics of Ataxias, treatment of Ataxia, and research on Ataxia.

ACT II will take place on March 30 – April 1, 2023.

Selected Fellows had the ability to interact with Ataxia experts, many of whom are reputable clinicians and scientists, and explore opportunities for specializing in this field which has a need for new talent and ideas, given we are ushering in an era of cutting-edge molecular, biopharmaceutical and bioengineering tools which hold significant promise for the cure of neurodegenerative disorders. The highlight of the ACT was virtual interactions between fellows and patients affected by a wide-spectrum of Ataxic disorders. Very few conferences offer the opportunity to bolster didactic knowledge with clinical experience making this course unique in its training scope.

HOW TO ATTEND ACT

We invite movement disorders fellows to participate in this program and gain clinical and scientific knowledge to effectively treat patients and families affected by Ataxia.

To be considered for this training, we request

A brief letter of interest from each fellow, approved by the fellowship director, about why they would like to participate in this program.
Name and contact information of the fellow and their program.

Correspondence should be addressed to Lauren Moore, NAF Chief Scientific Officer at lauren@ataxia.org.